Article - 20 Apr 2004
American Pharmaceutical Partners have announced that its cancer-fighting drug Abraxane has demonstrated greater tumour reduction and fewer side effects when compared to a solvent-dissolved equivalent....
News - 1 Jun 2009
Inc. (NASDAQ:ABII), a fully integrated global biotechnology company dedicated
to the discovery, development and delivery of next-generation therapeutics and
News - 2 Jul 2013
Sorrento Therapeutics, Inc. (Sorrento) and IGDRASOL announced today that the companies will present Phase III interim data analysis of Cynviloq in metastatic breast cancer (MBC) patients showing...
News - 27 Sep 2008
Paclitaxel is a powerful anticancer agent used to treat a variety of malignancies,
but severe side effects limit its ultimate effectiveness and utility. To improve
News - 13 Sep 2007
University chemists have discovered a way to load dozens of
molecules of the anti-cancer drug paclitaxel onto tiny gold spheres.
The result is a tiny ball, many times smaller than a living...
News - 18 Feb 2012
A research study by Jeffrey Myers from the University of Texas MD Anderson Cancer Center and James Tour from the Rice University has reported that a combination of carbon nanoparticles and existing...
News - 22 Jul 2015
Cerulean Pharma Inc. today announced that the first patient has been dosed in an open label Phase 1b clinical trial of its lead product candidate, CRLX101, in combination with weekly paclitaxel in...
News - 21 Apr 2015
Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical...
News - 4 Mar 2015
Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced it has signed a clinical research agreement with the GOG Foundation Inc. to conduct an open-label Phase 1b clinical...
News - 13 Jan 2015
Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that over 80 patients randomized in the ongoing TRIBECA™ (TRIal...